Skip to main content

New ibuprofen derivatives with thiazolidine-4-one scaffold with improved pharmaco-toxicological profile

Abstract

Background

Aryl-propionic acid derivatives with ibuprofen as representative drug are very important for therapy, being recommended especially for anti-inflammatory and analgesic effects. On other hand 1,3-thiazolidine-4-one scaffold is an important heterocycle, which is associated with different biological effects such as anti-inflammatory and analgesic, antioxidant, antiviral, antiproliferative, antimicrobial etc. The present study aimed to evaluated the toxicity degree and the anti-inflammatory and analgesic effects of new 1,3-thiazolidine-4-one derivatives of ibuprofen.

Methods

For evaluation the toxicity degree, cell viability assay using MTT method and acute toxicity assay on rats were applied. The carrageenan-induced paw-edema in rat was used for evaluation of the anti-inflammatory effect while for analgesic effect the tail-flick test, as thermal nociception in rats and the writhing assay, as visceral pain in mice, were used.

Results

The toxicological screening, in terms of cytotoxicity and toxicity degree on mice, revealed that the ibuprofen derivatives (4a-n) are non-cytotoxic at 2 μg/ml. In addition, ibuprofen derivatives reduced carrageenan-induced paw edema in rats, for most of them the maximum effect was recorded at 4 h after administration which means they have medium action latency, similar to that of ibuprofen. Moreover, for compound 4d the effect was higher than that of ibuprofen, even after 24 h of administration. The analgesic effect evaluation highlighted that 4 h showed increased pain inhibition in reference to ibuprofen in thermal (tail-flick assay) and visceral (writhing assay) nociception models.

Conclusions

The study revealed for ibuprofen derivatives, noted as 4 m, 4 k, 4e, 4d, a good anti-inflammatory and analgesic effect and also a safer profile compared with ibuprofen. These findings could suggest the promising potential use of them in the treatment of inflammatory pain conditions.

Peer Review reports

Background

Non-steroidal anti-inflammatory drugs (NSAIDs) in which aryl-propionic acid derivatives (ibuprofen, fenoprofen, ketoprofen, naproxen, etc.) have an important place, being among the most widely used pain drugs to treat pain and inflammation associated with rheumatic diseases but also the other types of pain such as renal colic, biliary colic, headache, dysmenorrhea, etc. [1].

Moreover, recent researches bring solid arguments regarding the beneficial effects of NSAIDs in neurodegenerative and cancer diseases, in which, inflammation and over-production of pro-inflammatory cytokines, as well as the oxidative stress, play an important role [2].

The epidemiological studies showed that more than 35 million people take daily NSAIDs and 40% of them are aged over 60 years. It also should be noted that annual sales of NSAIDs reach huge amounts that exceed $6 billion and for Europe NSAIDs prescriptions are more than 7.5% of all prescriptions issued in a year [1, 3].

On the other hand thiazolidine-4-one scaffold is one of the heterocycles that is widespread in the organic chemistry, being responsible for many biological effects [4] such as: anti-inflammatory and analgesic, antifungal and antimicrobial, anti-mycobacterial, antioxidant, antiviral and anti-HIV, anticonvulsant, hypoglycemic and antitumor effects [5].

Current researches aim the design and synthesis of hybrid molecules containing two or more pharmacophore scaffolds in order to improve the properties of the classical drugs or to induce new biological effects, providing in the same time a safer profile [6].

The aim of this work was to investigate the biological effects of the new derivatives of ibuprofen with thiazolidine-4-one scaffold synthesized by our research group [7], targeting the toxicity degree and the anti-inflammatory and analgesic effects.

Methods

Chemicals and reagents

Dulbecco’s Modified Eagle Medium (DMEM) with 4500 mg/ml glucose, 110 mg/l sodium pyruvate and 0.584 mg/l L-glutamine; Bovine Fetal Serum (BFS); Penicillin/ streptomycin/neomycin (P/S/N) solution with 5000 units penicillin, 5 mg streptomycin and 10 mg neomycin/ml; phosphate buffered saline; 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), ibuprofen, dimethylsulfoxide (DMSO), acetic acid, tween 80, k-carrageenan. All materials and reagents were purchased from Sigma-Aldrich. The thiazolidin-4-one derivatives of ibuprofen (4a-n, Fig. 1) were previously synthesized and characterized by our research group [7].

Fig. 1
figure1

The structure of ibuprofen derivatives with thiazolidine-4-one scaffold (4a-n)

Animals

Swiss albino mice and Wistar rats provided from the Biobase of “Grigore T. Popa” University of Medicine and Pharmacy from Iasi, were used. The animals were housed in polyethylene cages with access to water and food ad libitum for 7 days before starting the experiments. The environmental conditions during the study were maintained relatively constant at a 23 ± 2 °C temperature, 40–60% relative humidity and a 12 h light/dark cycle. The food and the water were withdrawn 18 h before starting the experiments. The animals (mice and rats respectively) were randomly divided into several groups (n = 8), depending of the method applied. The inclusion criteria used in the design of the experiment refer to the weight of animal (20–30 g for mice, 150–200 g for rats) and healthy state and the exclusion criteria applied were any pathological conditions observed to the animals. All the experiments were designed to cause minimum harm to animals. At the end of the experiments, the animals were anesthetized with ethyl ether and then the cervical dislocation procedure was used to euthanasia the animals. Prior to the disposal, the animal death was confirmed by observing the movement, heartbeat, respiration and eye reflex. All procedures were strictly conducted by the expert personnel and were in agreement with the guideline of laboratory animal studies.

Ethics approval and consent to participate

The study was conducted in agreement with actual deontology and ethics guidelines about laboratory animal studies (Law no. 206/27 May 2004, EU/2010/63 - CE86/609/EEC) and was approved by Research Ethics Committee of “Grigore T. Popa” University of Medicine and Pharmacy from Iasi (resolution no. 292).

Cell viability assay using the MTT method is based on the capacity of cell to reduce the slightly yellow tetrazolium salts to intense purple formazan by intracellular reduction system mostly located in the mitochondria. The amount of formazan, which is correlated with number of viable cells, is spectrophotometrically measured at 570 nm [8]. Primary cells, mesenchymal type with stem cell potential, isolated by collagenization from adipose tissue, were used. The cell line was maintained in DMEM supplemented with BFS (10%) and P/S/N in a humidified incubator with 5% CO2 at 37 °C. The cells were seeded in 24-well plates (104 cells/ml) and treated after 24 h with different concentrations of ibuprofen derivatives (4a-n) (50 μg/ml, 10 μg/ml, 2 μg/ml) for 24 h, 48 h and 72 h. DMSO was used as solvent and a negative control (blank, DMSO 0.2%) and a positive control (DMSO 5%) were used in similar conditions. The culture media was removed and MTT (500 μl) was next added to each well and the cells were further incubated for 3 h at 37 °C. The medium was then removed and isopropanol was added. After 15 min from each well were transferred 100 μl in a 96-well plate and the absorbance was recorded at 570 nm with a microplate reader [9, 10]. The cell viability rate was calculated using the following formula [9]:

$$ \mathrm{Cell}\ \mathrm{viability}\ \left(\%\right)=\left({\mathrm{A}}_{\mathrm{s}}/{\mathrm{A}}_{\mathrm{c}}\right)\times 100 $$

in which,

As = the absorbance of culture cells incubated with the sample (ibuprofen derivatives);

Ac = the absorbance of culture cells incubated with DMSO (0.2%).

The experiments were performed in triplicate and the results are presented as mean ± standard deviation (SD).

Acute toxicity assay was performed on mice and the tested compounds (4a-n) were suspended in tween 80 and administrated orally, in volume of 0.1 ml/10 g animal. The different doses (1000–3000 mg/kg body weight) of the tested compounds were used [11] and the survival rate was noted at the different timelines: 24, 48, 72 h and 7 and 14 days. The LD50 was calculated on base of Kärber arithmetic method [12] using the following formula:

$$ {\mathrm{LD}}_{50}={\mathrm{LD}}_{100}-\left(\sum \left(\mathrm{a}+\mathrm{b}\right)/\mathrm{n}\right), $$

in which:

a = the difference between two succesive doses of tested compounds;

b = the average number of dead animals in two successive doses;

n = the number of animals for each group;

LD100 = the lethal dose causing the 100% death of all test animals.

Carrageenan-induced paw edema assay was used to evaluate the anti-inflammatory effect, according to the protocols describes in the literature [13, 14] with slightly modifications. The edema was induced by intra-plantar administration of 0.2 ml of 1% suspension of k-carrageenan in physiological saline into the left hind paw of rat and the volume of paw was measured using the digital pletismometer LE. After induction of edema, the ibuprofen derivatives (4a-n) were administered orally in a daily dose representing 1/20 of LD50 as suspension in tween 80 (0.5 mL/100 g b.w.). Ibuprofen as reference drug and tween 80 (0.5 mL/100 g b.w.) as control, were used in similar conditions (Table 1).

Table 1 The doses (mg/kg b.w.) of ibuprofen derivatives (4a-n) used for anti-inflammatory and analgesic assays

The volume of the left hind paw was measured at different timelines (2, 4, 6 and 24 h). The edema inhibition (%) was calculated, using the following formula:

$$ \mathrm{Edema}\ \mathrm{inhibition}\ \left(\%\right)=\left(\Delta {\mathrm{V}}_{\mathrm{c}}-\Delta {\mathrm{V}}_{\mathrm{t}}\right)\ \mathrm{x}\ 100/\Delta {\mathrm{V}}_{\mathrm{c}} $$

in which:

ΔVc = the rat paw’s volume recorded for control group;

ΔVt = the rat paw’s volume recorded for groups treated with ibuprofen derivatives.

Analgesic effect

Tail-flick assay, used as model of thermal nociception is based on measuring the sensibility of rats when a thermal stimulus is applied on tail. According to the experimental protocol, the animals were initially tested by applying a radiant beam at the distal part of the tail, measuring the latency at time 0 (T0) [15, 16]. The response to pain was quantified using a Tail-flick algesimeter (Harvard Apparatus, United States of America). The ibuprofen derivatives (4a-n) were administered by oral gavage in a daily dose representing 1/20 of LD50, as suspension in tween 80 (0.5 mL/100 g b.w.) (Table 1). Ibuprofen, as reference drug, was used in similar conditions. In order to assess the analgesic effect, the initial response to pain and at 4 h after administration of ibuprofen derivatives (4a-n) it was determined. The maximum allowed time (cut-off time), for not causing tissue lesions was established to be 10 s (Tm).

The pain inhibition (%) was calculated for each tested compound, using the following formula:

$$ \mathrm{Pain}\ \mathrm{inhibition}\ \left(\%\right)=\left({\mathrm{T}}_{\mathrm{t}}-{\mathrm{T}}_0\right)/\left({\mathrm{T}}_{\mathrm{m}}-{\mathrm{T}}_0\right)\ \mathrm{x}\ 100 $$

in which:

Tt = the nociceptive response measured at 4 h after of ibuprofen derivatives administration;

T0 = the nociceptive response measured before any treatment (initially);

Tm = the maximum allowed time (cut-off time).

The presence of analgesic effect (anti-nociceptive potential) is highlighted by an increased latency response after administration of the ibuprofen derivatives in reference with the initially value.

Writhing assay is a model of visceral pain, induced to mice by intraperitoneal administration of acetic acid. It is characterized through abdominal contractions, body movements (especially of the posterior members), writhing of the dorsal-abdominal muscles with reduced locomotor activity. The applied experimental protocol was in agreement with the literature data with slightly modifications [17, 18]. The ibuprofen derivatives (4a-n) were administered by oral gavage in a daily dose representing 1/20 of LD50 as suspension in tween 80 (0.1 mL/10 g b.w.) (Table 1). Ibuprofen, as reference drug and tween 80 (0.1 ml/10 g b.w.), as control, were used in similar conditions. One hour after administration of tested compounds, the acetic acid (0.6% water solution), as irritating agent, in volume of 0.1 ml/10 g b.w. was intraperitoneally injected. After other 5 min the number of writhings for each mouse was noted, every 5 min, during 30 min. The analgesic effect, expressed as inhibition (%) of writhings was calculated for each tested compounds, using the following formula [14]:

$$ \mathrm{Inhibition}\ \left(\%\right)=\left({\mathrm{N}}_{\mathrm{c}}-{\mathrm{N}}_{\mathrm{t}}\right)\ \mathrm{x}\ 100/{\mathrm{N}}_{\mathrm{c}} $$

in which:

Nc = the writhings number recorded for mice from control group.

Nt = the writhings number recorded for mice of group treated with ibuprofen derivatives.

It is estimated that the analgesic activity is higher if the writhings number is decreased in comparison with control group.

Statistical analysis

Data are presented as mean ± standard deviation. The one-way analysis of variance (ANOVA) and Tukey post hoc test were used to determine whether there are any statistically significant differences between tested compounds and control. The p value < 0.05 was considered to be statistically significant.

Results

Cell viability assay

The cell viability values recorded for tested compounds (4a-n) at different concentrations (50 μg/ml, 10 μg/ml and 2 μg/ml) and at different timelines (24, 48 and 72 h) are presented at Tables 2, 3 and 4.

At 50 μg/ml was evidenced decreasing of cell viability with exposure time and the resulting percentages varied between 1.40 ± 0.26% to 64.25 ± 1.06% (24 h), from 1.14 ± 0.24% to 56.18 ± 0.88% (48 h) and from 0.34 ± 0.09% to 53.12 ± 1.65% (72 h). At this concentration, 4 m (R = 4-NH2) and 4n (R = 4-NHCOCH3), were the least toxic (Table 2).

Table 2 Cell viability (%) of ibuprofen derivatives (4a-n) at 50 μg/ml

An improving of cell viability was observed at 10 μg/ml, the values recorded ranging from 51.95 ± 1.42% to 97.51 ± 2.01% (24 h), from 41.04 ± 0.12 to 90.51 ± 0.66% (48 h) and from 41.03 ± 0.62% to 77.68 ± 1.59% (72 h) respectively. The less toxic derivatives were 4f (R = 3-NO2, 97.51 ± 2.01%), 4 k (R = 4-CN, 92.29 ± 0.33%) and 4n (R = 4-NHCOCH3, 95.25 ± 1.74%), the cell viability values being slightly increased (4f, 4n) or comparable (4 k) to ibuprofen (92.83 ± 2.24%) (Table 3).

Table 3 Cell viability (%) of ibuprofen derivatives (4a-n) at 10 μg/ml

For all compounds (4a-n) the cell viability values were higher than 70% at 2 μg/ml so they are considered non-cytotoxic [19] at this concentration (Table 4). The values of cell viability were ranged from 85.06 ± 2.01% to 99.64 ± 1.89% (24 h), from 77.07 ± 2.06% to 99.61 ± 1.53% (48 h) while the values were placed in 73.84–95.02% interval at 72 h. After 72 h the less toxic were 4 m (R = 4-NH2, 95.02 ± 1.46% 4f (R = 3-NO2, 94.44 ± 0.10%), 7c (R = 4-Br, 94.39 ± 1.65%), 4n (R = 4-NHCOCH3, 93.91 ± 1.96%).

Table 4 Cell viability (%) of ibuprofen derivatives (4a-n) at 2 μg/ml

Acute toxicity assay

Referring to the in vivo toxicity degree the data revealed that all tested compounds have showed to be less toxic compared with ibuprofen (LD50 = 1375 mg/kg b.w.) having the LD50 values ranged between 1565 mg/kg b.w. and 1840 mg/kg b.w. (Table 5). The less toxic derivatives were 4j (R = 4-CF3, LD50 = 1840 mg / kg b.w.), 4e (R = 2-NO2, LD50 = 1820 mg/kg b.w.) and 4 g (R = 4-NO2, LD50 = 1820 mg/kg b.w.) that proved to be about 1.3 times less toxic than ibuprofen.

Table 5 The values of LD50 recorded for ibuprofen derivatives (4a-n)

Carrageenan-induced paw edema assay

The new synthesized ibuprofen derivatives (4a-n) were tested at a dose of 1/20 LD50 and the results, expressed as edema inhibition (%) are show in Fig. 2. It can be noticed that at 2 h after administration, the edema inhibition (%) varied between 42.72 ± 4.55% and 61.81 ± 9.87%, for most part of the tested compounds the effect being comparable to the ibuprofen one (56.36 ± 7.87%). At this time the most active compounds were 4f (R = 3-NO2) and 4 k (R = 4-CN), for which the value of edema inhibition (%) was 61.81 ± 9.87%, slightly higher than ibuprofen. A noticeable activity, similar to that of ibuprofen, showed also 4e (R = 2-NO2), 4j (R = 4-CF3) and 4 m (R = 4-NHCOCH3), for which the value of edema inhibition was 56.36 ± 7.87%. The effect remained in quite similar range at 4 h after administration, the edema inhibition (%) ranging between 39.01 ± 2.81% and 68.52 ± 9.57%. At this timeline an appreciable effect was noted in case of 4d (R = 4-F) and 4f (R = 3-NO2), for which the edema inhibition (%) was 68.52 ± 9.57%. A similar effect was noted for 4j (R = 4-CF3) and 4 k (R = 4-CN), for which the inhibition edema (%) was 66.55 ± 10.72%. In similar condition the edema inhibition recorded for ibuprofen was 66.55 ± 10.72%.

Fig. 2
figure2

The edema inhibition (%) recorded for ibuprofen derivatives (4a-n) in comparison with ibuprofen at different timelines (the data represent the mean of 8 values ± standard deviation). One-way analysis of variance (ANOVA) followed by Tukey post hoc test was performed. & - p < 0.01 vs. vehicle, # - p < 0.001 vs. vehicle, * - p < 0.05 vs. ibuprofen, $ - p < 0.01 vs. ibuprofen, % - p < 0.001 vs. ibuprofen

At 6 h after administration the most active compounds were 4d (R = 4-F) and 4e (R = 2-NO2) for which the inhibition percentages of paw edema were 65.71 ± 10.49% and 60.81 ± 8.49%, being higher than ibuprofen value (43.67 ± 5.20%). The analysis of the data recorded at 24 h after administration, revealed a long lasting anti-inflammatory effect for tested derivatives, even slightly higher than ibuprofen for some of them. The most active compound proved to be 4d (R = 4-F), with an edema inhibition value of 53.04 ± 13.17%.

Analgesic effect

Tail-flick assay

Based on the value of reaction time of animals from the control group and the value of the maximum set time (10 s), for each group treated with ibuprofen derivatives (4a-n), the maximum effect, expressed as pain inhibition (%) was calculated (Fig. 3). The pain inhibition (%) recorded for ibuprofen derivatives ranged between 13.86 ± 1.19% and 75.67 ± 5.94%, while for ibuprofen the recorded value was 67.15 ± 8.66. The most active compounds proved to be 4 m (R = 4-NH2,75.67 ± 5.94%), 4 k (R = 4-CN, 75.36 ± 3.08%) and 4 h (R = 4-CH3, 74.45 ± 6.06%) for which the pain inhibition effect was higher than of that of ibuprofen.

Fig. 3
figure3

The pain inhibition (%) recorded for ibuprofen derivatives (4a-n) in comparison with ibuprofen at different timelines (the data represent the mean of 8 values ± standard deviation). One-way analysis of variance (ANOVA) followed by Tukey post hoc test was performed. # - p < 0.001 vs. vehicle, % - p < 0.001 vs. ibuprofen

The compounds 4n (R = 4-NHCOCH3, 69.59 ± 5.56%), 4i (R = 3-CF3, 68.37 ± 4.70%) and 4e (R = 2-NO2, 63.50 ± 6.49%) also showed an appreciable pain inhibitory effect, comparable with that of ibuprofen.

Writhing assay

From the analysis of the obtained results (Fig. 4) it is noticed a decrease of the writhings number in case of groups treated with ibuprofen derivatives (4a-n) in comparison to the control group, which means they could be appreciated having good analgesic effects.

Fig. 4
figure4

The inhibition of writhings (%) recorded for ibuprofen derivatives (4a-n) in comparison with ibuprofen (the data represent the mean of 8 values ± standard deviation). One-way analysis of variance (ANOVA) followed by Tukey post hoc test was performed. & - p < 0.01 vs. vehicle, # - p < 0.001 vs. vehicle, * - p < 0.05 vs. ibuprofen, $ - p < 0.01 vs. ibuprofen

The analgesic effect, expressed as inhibition of writhing number, was 52.37 ± 10.33% for ibuprofen while for the ibuprofen derivatives the recorded values varied between 23.38 ± 1.45% and 56.37 ± 10.30%. The most intense peripheral analgesic effect, higher than that of ibuprofen was recorded for 4 h (R = 4-CH3, 56.37 ± 10.30) and 4e (R = 2-NO2, 53.06 ± 10.63). Appreciable effects, comparable to that of ibuprofen, were showed also by 4a (R = H, 52.37 ± 11.39), 4j (R = 4-CF3, 50.58 ± 12.69), 4 k (R = 4-CN, 50.30 ± 11.52), 4f (R = 3-NO2, 49.47 ± 5.02), 4 g (R = 4-NO2, 49.47 ± 10.92), 4 m (R = 4-NH2, 49.19 ± 5.62) and 4b (R = 4-Cl, 47.31 ± 7.54).

Discussion

Ibuprofen is a widely used nonsteroidal anti-inflammatory drug which belongs to aryl-propionic acid derivatives. It acts mainly as nonselective inhibitor of both cyclooxygenase (COX) enzymes (COX-1 and COX-2). Its free carboxyl group allows a variety of structural modification and is also responsible for a part of side effects that could appear at gastric, renal or liver level. It was noted that modifying the carboxyl group could lead to compounds that become more selective for COX-2 isoform. Some pharmacophores such as two aromatic rings seem to be also responsible for COX-2 selectivity by fitting in the enzyme structure [20]. Starting from ibuprofen, new thiazolidine-4-one derivatives have been synthesized by our research group [7], as candidates to alleviate the pain or inflammation associated with various pathological conditions. To prove the therapeutic potential of the synthesized derivatives a pharmaco-toxicological screening that has included in vitro and in vivo assays, was performed.

The MTT cell viability assay is an in vitro colorimetric assay, which determines the mitochondria activity, hence providing information on cellular energy metabolism [9, 10]. It was observed that the values of cell viability recorded for tested compounds (4a-n) at 50 μg/ml decrease in time, a good cell viability being recorded for 4 m (R = 4-NH2) and 4n (R = 4-NHCOCH3) at all timelines (24 h, 48 h, 72 h). An improving of cell viability was observed at 10 μg/ml, for some derivatives (4f, R = 3-NO2; 4 k, R = 4-CN and 4n, R = 4-NHCOCH3) the value recorded being comparable with of ibuprofen one, especially at 24 h. At 2 μg/ml, all tested compounds (4a-n) are considered non-cytotoxic because the values of cell viability are higher than 70% and comparable with ibuprofen at all timelines. The leader compound in view of citotoxicity seems to be 4n, for which the values of cell viability recorded for all tested concentrations (50 μg/ml, 10 μg/ml and 2 μg/ml) support its non-citotoxicity. These results support the favorable influence of NHCOCH3 substituent on aromatic ring in view of decreasing of the cytotoxicity degree.

The acute toxicity, expressed by median lethal dose 50 (LD50), represents the base for toxicological classification of substances [21, 22]. It is knows that toxicity is responsible for many side effects, which could appear either immediately or after a time, following administration of a single dose or multiple doses of the substance in 24 h. All tested ibuprofen derivatives (4a-n) are slightly toxic, the values of LD50 being higher than of ibuprofen one. So, it could be appreciated that chemical modulation of ibuprofen using thiazolidine-4-one scaffold leads to decreasing of the toxicity. In addition, the substitution of aromatic ring of thiazolidine-4-one scaffold seems to have favorable influence for reducing the toxicity degree.

Carrageenan-induced paw edema is a widely used experimental acute inflammation model to assess the anti-inflammatory action of compounds designed as potential anti-inflammatory agents [23,24,25,26]. This model involves many mediators such as prostaglandins, cytokines, histamine and bradykinin that stimulate the inflammatory process [27,28,29]. Our study demonstrated that all tested ibuprofen derivatives reduced paw edema, for the most part of them the effect being comparable to that of ibuprofen, used as reference drug. For the most of them (4a-g, 4j, 4 k, 4n) the maximum effect was recorded after 4 h of administration, similar to ibuprofen, which means they are considered compounds with medium action latency. For 4 h (R = 4-CH3), 4i (R = 3-CF3), 4 l (R = 2,6-diCl) and 4 m (R = 4-NH2) the maximum effect was recorded after 2 h of administration, which means they have short action latency. The most proper compounds proved to be 4d (R = 4-F), 4a (R = −H), 4e (R = 2-NO2), 4 g (R = 4-NO2) and 4f (R = 3-NO2), for which a long-term anti-inflammatory effect was recorded. In addition, the effect of these compounds was higher or comparable to that of ibuprofen, used as reference drug, at all studied time intervals (2, 4, 6 and 24 h).

The tail-flick assay is a pain receptive model which measures animal nociceptive response latencies to thermal stimulus, based mainly on spinal response [30]. It is known that the response to pain and the reaction time to painful stimulus are mediated at the central nervous system level, and more specific, at the spinal level [31]. It is consider that the substances which present an increase in reaction time to painful stimulus, compared to the control, are considered to have analgesic potential. In our study the influence of chemical modulation of ibuprofen on pain inhibition effect was noticed. It could be appreciate that the best influence was showed by radicals 4-NH2, 4-CN and 4-CH3, which substitute the aromatic ring of thiazolidine-4-one scaffold, the corresponding compounds (4 m, 4 k and 4 h) being more active than ibuprofen.

Writhing assay is a model used to evaluate the inhibition effect of visceral pain, considering the behavioral modifications, in terms of abdominal contortions [32]. The most intense peripheral analgesic effect was recorded for 4 h (R = 4-CH3) and 4e (R = 2-NO2), for which the analgesic effect was higher than of ibuprofen. The findings of analgesic assays based on central and visceral mediated pain, suggest that both mechanisms are involved in the anti-nociceptive activity of the tested compounds.

Conclusions

In this study the toxicity degree as well as the anti-inflammatory and analgesic effects of new ibuprofen derivatives with thiazolidine-4-one scaffold, using in vitro and in vivo assays have been reported. The results highlighted the therapeutic potential of four ibuprofen derivatives (4 m, 4 k, 4e, 4d) for different disorders where inflammation and pain play an important role such as inflammatory, neurodegenerative and cancer diseases.

Availability of data and materials

The data supporting the conclusions of this article are incuded in the article. The supplementary can be requested from the corresponding author.

Abbreviations

NSAIDs:

Non-steroidal anti-inflammatory drugs

DMEM:

Dulbecco’s Modified Eagle Medium

BFS:

Bovine Fetal Serum

P/S/N:

Penicillin/streptomycin/neomycin

MTT:

3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide

DMSO:

Dimethylsulfoxide

SD:

Standard deviation

LD50 :

Lethal dose 50

b.w.:

Body weight

References

  1. 1.

    Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly. Aging Dis. 2018;9(1):143–50.

    Article  Google Scholar 

  2. 2.

    Zhang Z, Chen F, Shang L. Advances in antitumor effects of NSAIDs. Cancer Manag Res. 2018;10:4631–40.

    CAS  Article  Google Scholar 

  3. 3.

    Pilotto A, Sancarlo D, Addante F, Scarcelli C, Franceschi M. Non-steroidal anti-inflammatory drug use in the elderly. Surg Oncol. 2010;19(3):167–72.

    Article  Google Scholar 

  4. 4.

    Ghafoori H, Rezaei M, Mohammadi A. Anti-inflammatory effects of novel thiazolidinone derivatives as bioactive heterocycles on RAW264.7 cells. Iran J Allergy Asthma Immunol. 2017;16(1):28–38.

    PubMed  Google Scholar 

  5. 5.

    Kaur Manjal S, Kaur R, Bhatia R, Kumar K, Singh V, Shankar R, Kaur R, Rawal RK. Synthetic and medicinal perspective of thiazolidinones: a review. Bioorg Chem. 2017;75:406–23.

    CAS  Article  Google Scholar 

  6. 6.

    Pawełczyk A, Sowa-Kasprzak K, Olender D, Zaprutko L. Molecular consortia-various structural and synthetic concepts for more effective therapeutics synthesis. Int J Mol Sci. 2018;19(4):1104.

    Article  Google Scholar 

  7. 7.

    Vasincu IM, Apotrosoaei M, Panzariu AT, Buron F, Routier S, Profire L. Synthesis and biological evaluation of new 1,3-thiazolidine-4-one derivatives of 2-(4-isobutylphenyl) propionic acid. Molecules. 2014;19(9):15005–25.

    Article  Google Scholar 

  8. 8.

    Lim SW, Loh HS, Ting KN, Bradshaw TD, Allaudin ZN. Reduction of MTT to purple formazan by vitamin E isomers in the absence of cells. Trop Life Sci Res. 2015;26(1):111–20.

    PubMed  PubMed Central  Google Scholar 

  9. 9.

    Racles C, Iacob M, Butnaru M, Sacarescu L, Cazacu M. Aqueous dispersion of metal oxide nanoparticles, using siloxane surfactants. Colloid Surf A - Physicochem Eng Asp. 2014;448:160–8.

    CAS  Article  Google Scholar 

  10. 10.

    Macocinschi D, Filip D, Vlad S, Butnaru M, Knieling L. Evaluation of polyurethane based on cellulose derivative-ketoprofen biosystem for implant biomedical devices. Int J Biol Macromol. 2013;52:32–7.

    CAS  Article  Google Scholar 

  11. 11.

    Ranganathan A, Hindupur R, Vallikannan B. Biocompatible lutein-polymer-lipid nanocapsules: acute and subacute toxicity and bioavailability in mice. Mater Sci Eng C. 2016;69:1318–27.

    CAS  Article  Google Scholar 

  12. 12.

    Ramakrishnan MA. Determination of 50% end point titer using a simple formula. World J Virol. 2016;5(2):85–6.

    Article  Google Scholar 

  13. 13.

    Oliveira PA, de Almeida TB, de Oliveira RG, Gonçalves GM, de Oliveira JM, Neves dos Santos BB, Laureano-Melo R, WDS C, TDN F, MLAA V, Marinho BG. Evaluation of the antinociceptive and anti-inflammatory activities of piperic acid: involvement of the cholinergic and vanilloid systems. Eur J Pharmacol. 2018;834:54–64.

    CAS  Article  Google Scholar 

  14. 14.

    Nayak A. In vitro and in vivo study of poly(ethylene glycol) conjugated ibuprofen to extend the duration of action. Sci Pharm. 2011;79(2):359–73.

    CAS  Article  Google Scholar 

  15. 15.

    Reis GM, Fais RS, Prado WA. The antinociceptive effect of stimulating the retrosplenial cortex in the rat tail-flick test but not in the formalin test involves the rostral anterior cingulate cortex. Pharmacol Biochem Behav. 2015;131:112–8.

    CAS  Article  Google Scholar 

  16. 16.

    Le Bars D, Gozariu M, Cadden SW. Animal models of nociception. Pharmacol Rev. 2001;53(4):597–652.

    PubMed  PubMed Central  Google Scholar 

  17. 17.

    De Oliveira AM, Conserva LM, De Souza Ferro JN, Brito FDA, Lemos RPL, Barreto E. Antinociceptive and anti-inflammatory effects of octacosanol from the leaves of Sabicea Grisea Var. Grisea in mice. Int J Mol Sci. 2012;13(12):1598–611.

    Article  Google Scholar 

  18. 18.

    Gupta AK, Parasar D, Sagar A, Choudhary V, Chopra BS, Garg R, Ashish KN. Analgesic and anti-inflammatory properties of Gelsolin in acetic acid induced writhing, tail immersion and carrageenan induced paw edema in mice. PLoS One. 2015;10(8):e0135558.

    Article  Google Scholar 

  19. 19.

    Butruk BA, Ziętek PA, Ciach T. Simple method of fabrication of hydrophobic coatings for polyurethanes. Cent Eur J Chem. 2011;9(6):1039–45.

    CAS  Google Scholar 

  20. 20.

    Ahmadi A, Khalili M, Ahmadian S, Shahghobadi N, Nahri-Niknafs B. Synthesis and pharmacological evaluation of new chemical entities based on paracetamol and their ibuprofen conjugates as novel and superior analgesic and anti-inflammatory candidates. Pharm Chem J. 2014;48:109–15.

    CAS  Article  Google Scholar 

  21. 21.

    Paramveer DS, Chanchal MK, Paresh M, Asha R, Shrivastava B, Rajesh KN. Effective alternative methods of LD50 help to save number of experimental animals. J Chem Pharm Res. 2010;2(6):450–3.

    Google Scholar 

  22. 22.

    Vasincu A, Ababei DC, Arcan OD, Bulea D, Neamţu M, Chiriac SB, Bild V. Preliminary experimental research on acute toxicity of Vernonia Kotschyana extracts in mice. Vet Drug. 2018;12(1):57–62.

    Google Scholar 

  23. 23.

    Martinez RM, Longhi-Balbinot DT, Zarpelon AC, Staurengo-Ferrari L, Baracat MM, Georgetti SR, Sassonia RC, Verri WA Jr, Casagrande R. Anti-inflammatory activity of betalain-rich dye of Beta vulgaris: effect on edema, leukocyte recruitment, superoxide anion and cytokine production. Arch Pharm Res. 2015;4:494–504.

    Article  Google Scholar 

  24. 24.

    Mahapatra DK, Dadure KM, Shivhare RS. Edema reducing potentials of some emerging Schiff’s bases of murrayanine. MOJ Biorg Org Chem. 2018;2(4):171–4.

    Google Scholar 

  25. 25.

    Srivastava AR, Bhatia R, Chawla P. Synthesis, biological evaluation and molecular docking studies of novel 3,5-disubstituted 2,4-thiazolidinediones derivatives. Bioorg Chem. 2019;89:102993.

    Article  Google Scholar 

  26. 26.

    Abdellatif KRA, Fadaly WAA, Kamel GM, Elshaier Y, El-Magd MA. Design, synthesis, modeling studies and biological evaluation of thiazolidine derivatives containing pyrazole core as potential anti-diabetic PPAR-γ agonists and anti-inflammatory COX-2 selective inhibitors. Bioorg Chem. 2019;82:86–99.

    CAS  Article  Google Scholar 

  27. 27.

    Karim N, Khan I, Khan W, Khan I, Khan A, Halim SA, Khan H, Hussain J, Al-Harrasi A. Anti-nociceptive and anti-inflammatory activities of asparacosin a involve selective cyclooxygenase 2 and inflammatory cytokines inhibition: an in-vitro, in-vivo, and in-silico approach. Front Immunol. 2019;10:581.

    CAS  Article  Google Scholar 

  28. 28.

    Singh G, Singh G, Bhatti R, Gupta M, Kumar A, Sharma A, Ishar MPS. Indolyl-isoxazolidines attenuate LPS-stimulated pro-inflammatory cytokines and increase survival in a mouse model of sepsis: identification of potent lead. Eur J Med Chem. 2018;153:56–64.

    CAS  Article  Google Scholar 

  29. 29.

    Galvão GM, Florentino IF, Sanz G, Vaz BG, Lião LM, Sabino JR, Cardoso CS, da Silva DPB, Costa EA, Silva ALP, da Silva ACG, Valadares MC, Leite JA, de S Gil E, Menegatti R. Anti-inflammatory and antinociceptive activity profile of a new lead compound - LQFM219. Int Immunopharmacol. 2020;88:106893.

    Article  Google Scholar 

  30. 30.

    Santenna C, Kumar S, Balakrishnan S, Jhaj R, Ahmed SN. A comparative experimental study of analgesic activity of a novel non-steroidal anti-inflammatory molecule - zaltoprofen, and a standard drug - piroxicam, using murine models. J Exp Pharmacol. 2019;11:85–91.

    CAS  Article  Google Scholar 

  31. 31.

    Mischkowski D, Palacios-Barrios EE, Banker L, Dildine TC, Atlas LY. Pain or nociception? Subjective experience mediates the effects of acute noxious heat on autonomic responses. Pain. 2018;159(4):699–711.

    Article  Google Scholar 

  32. 32.

    Lenardão EJ, Savegnago L, Jacob RG, Victoria FN, Martinez DM. Antinociceptive effect of essential oils and their constituents: an update review. J Braz Chem Soc. 2016;27(3):435–74.

    Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This study was financially supported by University of Medicine and Pharmacy “Grigore T. Popa” Iasi, based on contracts no. 23401/07.11.2018 and 30341/28.12.2017 and by the grant of UEFISCDI, PN III Program, AUF-RO, AUF-IFA 2019–2020, contract no. 28/2019. The study funders had no further role in the study design, data collection, analyses, interpretation of results, writing of the article, or the decision to submit it for publication.

Author information

Affiliations

Authors

Contributions

LP, SR, FB, IMV designed the study. IMV, MA, SC, MB performed the research. IMV, LV, CEL, LP, DR analyzed the data. IMV, DL, RGT prepared the article. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Sylvain Routier or Lenuța Profire.

Ethics declarations

Ethics approval and consent to participate

Animal experiments were approved by the Research Ethics Committee of “Grigore T. Popa” University of Medicine and Pharmacy from Iasi (resolution no. 292).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Vasincu, IM., Apotrosoaei, M., Constantin, S. et al. New ibuprofen derivatives with thiazolidine-4-one scaffold with improved pharmaco-toxicological profile. BMC Pharmacol Toxicol 22, 10 (2021). https://doi.org/10.1186/s40360-021-00475-0

Download citation

Keywords

  • Ibuprofen
  • Thiazolidine-4-one
  • Toxicity degree
  • Anti-inflammatory and analgesic effects